Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Experimental immune cell therapy for liver cancer hits early roadblock

NCT ID NCT04502082

Disease control Sponsor: Eureka Therapeutics Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This early-stage trial tested a new type of immune cell therapy (ET140203 T cells) in 8 adults with advanced liver cancer that had not responded to other treatments. The therapy was designed to target a protein called AFP found on cancer cells. The study was terminated early, so we have very limited information on safety or effectiveness.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
engineered immune cells (ET140203 T cells)
What this could lead to
If this approach had worked, it could have pointed toward a new treatment option for people with advanced liver cancer who have run out of standard therapies.
What could go wrong
This was a very early, small trial that was terminated before completion. The therapy may not be effective or safe enough, and it is unclear if it will ever be tested further.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

8 people

The number who actually took part.

Started

Apr 2021

Finished

Aug 2024

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Histologically confirmed HCC with serum AFP \>100ng/ml at time of screening and following most current line of therapy OR radiographic diagnosis of HCC with serum AFP \>400ng/ml at time of screening and following most current line of therapy. * Metastatic or locally advanced, unresectable HCC * Must have failed or not tolerated at least two (2) different anti-HCC systemic agents * Molecular Human Leukocyte Antigen ("HLA") class I allele typing confirms participant carries at least one HLA-A2 allele * Life expectancy of at least 4 months * Karnofsky Performance Scale greater than or equal to 70 * At least 1 measurable lesion on imaging by RECIST * Child-Pugh A6 or better * Absolute neutrophil count greater than or equal to 1,500/mm\^3 * Platelet count greater than or equal to 75,000/mm\^3 Exclusion Criteria: * Clinically significant cardiac disease * Clinically significant pre-existing illness or active infection * Clinically significant Central Nervous System (CNS) or neural dysfunction * Active autoimmune disease requiring therapy * Active malignancy other than HCC with the exception of cholangiocarcinoma (CCA) or any malignancy with an expected survival ≥ 3 years without any treatment (exception: hormone/androgen-deprivation therapy) and without any organ involvement * History of organ transplant * Compromised circulation in portal vein, hepatic vein, or vena cava due to obstruction * Advanced HCC involving greater than 50% of the liver

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hepatocellular carcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma liver and intrahepatic bile duct neoplasm liver cancer Liver Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hepatocellular carcinoma Liver cancer Liver neoplasm Metastatic liver cancer

Contacts and locations

Locations

  • City of Hope Medical Center

    Duarte, California, 91010, United States

  • Kansas University Medical Center

    Westwood, Kansas, 66205, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.